Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etifoxine add-on treatment for depressive disorders
2021-006773-38Phase 2Active
- Sponsor
- medbo
- Start
- Sep 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and bipolar disorder (BD) comparing Etifoxine + treatment as usual with Placebo + treatment as usual (2 arms). Primary endpoint: ET50 based on HAMD-21. Started Sep 2022; status: active.
02
Drugs
etifoxine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on 2021-006773-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006773-38.